BCL2 and plasma cell myeloma: Clinically, venetoclax as a monotherapy is highly efficacious in Chronic Lymphocytic Leukemia (CLL) (that is BCL-2 dependent) [170]; however, effective only in a minority contingent of MM [171], with a recent phase 1 study suggesting only selective efficacy within the 11;14 myeloma patients [172].